Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2010 - 2025)
Rigel Pharmaceuticals (RIGL) posted quarterly Other Non-Current Liabilities of $5.0 million for Q3 2025, little changed year-over-year from $5.0 million in Q3 2024, and little changed quarter-over-quarter from $5.0 million in Q2 2025.
Rigel Pharmaceuticals (RIGL) Other Non-Current Liabilities (2010 - 2025) Analysis & Trends
Rigel Pharmaceuticals' Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $5.0 million for Q3 2025.
- In Q3 2025, Other Non-Current Liabilities changed 0.0% year-over-year to $5.0 million; the TTM figure through Sep 2025 stood at $5.0 million (changed 0.0% YoY), while the FY2024 annual figure was $5.0 million, down 87.48% from the prior year.
- Other Non-Current Liabilities for Q3 2025 stood at $5.0 million, roughly flat from $5.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $57.5 million in Q1 2021, with the low at $5.0 million in Q3 2024.
- The 5-year median for Other Non-Current Liabilities is $41.0 million (2023), against an average of $34.5 million.
- The sharpest annual moves came in 2021 and 2024: Other Non-Current Liabilities soared 1050.66% in 2021, then tumbled 87.48% in 2024.
- Rigel Pharmaceuticals' Other Non-Current Liabilities stood at $52.7 million in 2021, then dropped by 19.84% to $42.3 million in 2022, then dropped by 5.49% to $39.9 million in 2023, then sank by 87.48% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
- Business Quant data shows RIGL's Other Non-Current Liabilities at $5.0 million in Q3 2025, $5.0 million in Q2 2025, and $40.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 39.98 Mn |
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 15.22 Mn |
| Dec 31, 2023 | 39.94 Mn |
| Sep 30, 2023 | 38.76 Mn |
| Jun 30, 2023 | 40.98 Mn |
| Mar 31, 2023 | 42.07 Mn |
| Dec 31, 2022 | 42.26 Mn |
| Sep 30, 2022 | 48.71 Mn |
| Jun 30, 2022 | 46.89 Mn |
| Mar 31, 2022 | 53.20 Mn |
| Dec 31, 2021 | 52.73 Mn |
| Sep 30, 2021 | 54.37 Mn |
| Jun 30, 2021 | 48.23 Mn |
| Mar 31, 2021 | 57.53 Mn |
| Dec 31, 2020 | 5.05 Mn |